Cell therapy weekly: US FDA clears cell therapy for Phase I trial in patients with advanced Parkinson’s disease

Written by RegMedNet

This week: the US FDA has cleared an IND application for a cell therapy candidate to proceed with a Phase I study in patients with advanced Parkinson’s disease, a cryopreserved amniotic suspension allograft for knee osteoarthritis receives RMAT designation, and Capricor enters a collaboration with Lonza to develop its cell therapy candidate for Duchenne muscular dystrophy. The news highlights: US FDA clears cell therapy for Phase I trial in patients with advanced Parkinson’s disease ReNu® receives RMAT for the management of symptoms associated with knee osteoarthritis Lonza and Capricor collaborate to develop cell therapy candidate for Duchenne muscular dystrophy  ...

To view this content, please register now for access

It's completely free